Expanding Frontotemporal Dementia Gene Therapy to Both GRN and C9orf72 Mutations
William Chou, MD, president and chief executive officer of Passage Bio, discussed feedback from a recent Type C meeting with the FDA.
CGTLive®’s Weekly Rewind – October 25, 2024
Review top news and interview highlights from the week ending October 25, 2024.
Around the Helix: Cell and Gene Therapy Company Updates – October 23, 2024
Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.
CGTLive®’s Weekly Rewind – October 18, 2024
Review top news and interview highlights from the week ending October 18, 2024.
Around the Helix: Cell and Gene Therapy Company Updates – October 16, 2024
CGTLive®’s Weekly Rewind – October 11, 2024
Review top news and interview highlights from the week ending October 11, 2024.
